DOCSLIB.ORG

Tiratricol (TRIAC) Than Are T4 and T3' the Liver Appears to Be the Major Site of Degradation of Tiratricol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tiratricol (TRIAC) Than Are T4 and T3' the Liver Appears to Be the Major Site of Degradation of Tiratricol 616/TIN PDR FOR NUTRITIONAL SUPPLEMENTS Pekelharing HL, Lemmens AG, Beynan AC. Iron, copper and PHARMACOKINETICS zinc status in rats fed on diets containing various concentrations Much is unknown about the pharmacokinetics of tiratricol in of tin. Br J Nutr. 1994; 71: 103-109. humans. The pharmacokinetics of tiratricol appears to be Yokoi K, Kimura M, Itokawa Y. Effect of dietary tin similar to those of thyroxine and triiodothyronine. Tiratricol deficiency on growth and mineral status in rats. Bioi Trace is absorbed from the small intestine following ingestion. Elem Res. 1990; 223-231. Distribution of tiratricol in the body has not been fully elucidated. Most of this substance appears to be bound to serum proteins, including thyroxine-binding protein and albumin. It appears to be less firmly bound to serum proteins Tiratricol (TRIAC) than are T4 and T3' The liver appears to be the major site of degradation of tiratricol. Tiratricol appears to be conjugated FDA warns against consuming dietary supplements with glucuronic acid and sulfuric acid and excreted in the containing Tiratricol. bile. Mainly because it is less tightly bound to serum proteins, tiratricol has a shorter half-life than T4 or T3, DESCRIPTION INDICATIONS AND USAGE Tiratricol is an orphan drug for use in combination with The FDA has warned consumers not to purchase tiratricol- levothyroxine to suppress thyroid stimulflting hormone containing dietary supplements due to risk of serious health (TSH) in patients with well-differentiated thyroid cancer consequences, including heart attacks and strokes. Tiratricol who are intolerant to adequate doses of levothyroxine alone. should be used only under a 'physician's supervision. Tiratricol is a metabolite of the thyroid hormone triiodothy- Tiratricol is currently used by some as a supplement to burn ronine (T3) and has thyroid hormone activity. fat. The doses required to achieve this effect pose significant Tiratricol is also marketed as a dietary supplement for health risks. weight-loss purposes. In November 2000, the Food and Drug Administration (FDA) warned against consuming dietary RESEARCH SUMMARY supplements containing tiratricol. This was based on reports Tiratricol is an orphan drug. The FDA has determined that it of individuals using tiratricol developing side effects, such as should not be used as a dietary supplement due to serious fatigue, lethargy, profound weight loss and severe diarrhea. potential health risks including heart attack and stroke. They were also found to have abnormal thyroid function tests. Further action by the FDA is being considered. CONTRAINDICATIONS,, PRECAUTIONS, ADVERSE REACTIONS CONTRA INDICA TIONS Tiratricol is also known as triiodothyroacetic acid, TRIAC, Tiratricol is contraindicated in those with untreated thyrotox- 3,5,3' -triiodothyroacetic acid and [4-(4-hydroxy-3-iodophe- icosis of any etiology and in those with uncorrected adrenal noxy)-3,5-di-iodophenyl]acetic acid. Its molecular formula is insufficiency. Thyroid hormones increase tissue demands for C14H91304,and its molecular weight is 621.9 daltons. adrenocortical hormones and may thereby precipitate acute adrenal crisis. Tiratricol is also contraindicated in those who ACTIONS AND PHARMACOLOGY are hypersensitive to any component of a tiratricol-contain- ACTIONS ing product. FDA warns against consuming dietary supple- Tiratricol has thyroid hormone activIty, including various ments containing tiratricol. metabolic effects. It also inhibits the secretion of thyroid- stimulating hormone (TSH) by the pituitary gland. Tiratricol PRECAUTIONS is a product of triiodothyronine or T3 metabolism, derived by Tiratricol should only be used for specific approved indica- deamination and oxidative decarboxylation of the alanine tions and only under strict medical supervis~on. Tiratricol chain. In humans, tiratricol production by the liver and other should not be used as a treatment for obesity. Tiratricol tissues accounts for about 14% of T3 metabolism and is should be used with extreme caution in those with cardiovas- increased under certain physiological conditions, such as , cular disorders (including flngina, coronary artery disease fasting. Tiratricol may play a role in regulat.ing energy and hypertension) and in the elderly who have a greater balance. likelihood of occult cardiac disease. Concomitant use of MECHANISM OF ACTION tiratricol and sympathomimetic agents in those with coronary The mechanism by which thyroid hormones exert their artery disease may increase the risk of coronary insufficien- various actions has not been completely elucidated. Tiratri- cy. Use of tiratricol in those with concomitant diabetes col is known to act as a feedback inhibitor of TSH secretion mellitus, diabetes insipidus or adrenal cortical insufficiency by the pituitary gland. may aggravate the intensity of their symptoms. SUPPLEMENT MONOGRAPHS TOCOTR IENOLS /617 FDA warns against consuming dietary supplements contain- a child with thyroid hormone resistance. Thyroid. 1997;7:775- ing tiratricoI. 778. Takeda T, Suzuki S, Uu RT, et al. Triiodothyroacetic acid has ADVERSE REACTIONS unique potential for therapy of resistance to thyroid hormone. J Reported adverse reactions include fatigue, lethargy, pro- Clin Endocrinol Metab. 1995;80:2033-2040. found weight loss and severe diarrhea. Tir~tricol has also been reported to cause abnormal thyroid function tests. INTERACTIONS DRUGS Tocotrienols Anticoagulants (oral). The hypoprothrombinemic effect of DESCRIPTION anticoagulants, such as warfarin, may be potentiated. Tocotrienols comprise one of the two groups of molecules Sympathomimetic agents. There is a possible increased risk belonging to the vitamin E family, the other group being the of coronary insufficiency in those with coronary artery tocopherols. Tocotrienols and tocopherols are sometimes disease. collectively called tocols. Just as there are four natural tocopherols, alpha-, beta-, gamma- and delta-tocopherol, Thyroid drugs (levothyroxine, tr,iiodothyronine, thyroid). there are also four natural tocotrienols, alpha-, beta-, gamma- Concomitant use of tiratricol with the~e thyroid drugs is and delta-tocotrienoI. The tocotrienols differ from the likely to produce additive effects. tocopherols in the chemical nature of the side chain or tail. Tocopherols have a saturated phytyl side chain, whereas LABORATORY TESTS tocotrienols have an unsaturated isoprenoid or farnesyl side Tiratricol is likely to alter thyroid function tests, including chain ,possessing three double bonds. TSH, 'f,4 and T3' OVERDOSAGE The major source of tocotrienols are plant oils, and the There have been no reports of overdosage with tiratricoI. richest sources are palm oil, rice bran oil, palm kernel oil and Excessive doses of tiratricol theoretically may result in a coconut oil. Tocotrienols are also found in such cereal grains hyperrnetabolic state indistinguishable from thyrotoxicosis. as oat, barley and rye. Vegetable oils, such as those from canola, cottonseed, olive, peanut, safflower, soybean and DOSAGE AND ADMINISTRATION sunflower, contain little to no tocotrienols. However, those Tiratricol is not recommended for use as a dietary oils do contain tocopherols. Corn oil has small amounts of supplement. tocotrienols. LITERATURE All of the natural tocotrienols are fat-soluble, water-insoluble Anon. FDA warns against consuming dietary supplements oils. The tocotrienols, as well as the tocopherols, possess containing tiratricol. FDA Talk Paper. Nov. 21, 2000. chain-breaking, peroxyl radical scavenging activities. In Bracco D, Morin 0, Schutz Y, et al. Comparison of the contrast to tocopherols, tocotrienols inhibit the rate- metabolic effects of 3,5,3' -triiodothyroacetic acid and thyroxine. limiting enzyme of the cholesterol biosynthetic pathway J Clin Endocrin Met. 1993;77:221-228. beta-hydroxy-beta-methylglutaryl-coenzyme A (HMG-CoA) Darendeliler F, Ba F. Successful therapy with 3,5,3'- reductase. triiodothyroacetic acid (TRIAC) in pituitary resistance to thyroid hormone. J Pediatr Endocrinol Metab. 1997;10(5):535-538. The four natural tocotrienols are characterized by the number of methyl groups and their position in the chromanol ring. Iglesias P, Dfez 11. [Therapeutic possibilities in patients with Alpha-tocotrienol has three methyl groups located on posi- selective pituitary resistance to thyroid hormones.] [In Spanish.] Med Clin (Barc). 2008;130(9):345-350. tions 5, 7 and 8 of the chromanol ring; beta-tocotrienol has two methyl groups located on positions 5 and 8 of the ring; Medina-Gomez G, Calvo RM, Obregon MJ. Thermogenic eff~ct gamma-tocotrienol has two methyl groups located on posi- of triiodothyroacetic acid at low doses in rat adipose tissue tions 7 and 8 of the ring and delta-tocotrienol has one methyl without adverse side effects in the thyroid axis. Am J Physiol Endocrinol Metab. 2008;294(4):E688-697. group located on position 8 of the ring. Pisarev MA, Brenta G, Schnitman M, et al. [Triiodothyroacetic While tocopherols have three chiral centers, tocotrienols acid in euthyroid goiter. New data on its mechanisms of action. have only one chiral center. Therefore, each tocotrienol has Comparison with L-thyroxin.] [In French.] Bull Acad Natl Med. two stereoisomeric possibilities in comparison with eight 2007;191(8):1705-1715; discussion 1715. such possibilities for each of the tocopherols. The natural Radetti G, Persani L, Molinaro G, et al. Clinical and hormonal tocotrienols exist as d-stereoisomers: d-alpha-tocotrienol, d- outcome after two years of triiodothyroacetic acid treatment in beta-tocotrienol, d-gamma-tocotrienol and d-delta-tocotrien-.
Load more

Recommended publications
  • Thyroid Hormone Misuse and Abuse
    Endocrine (2019) 66:79–86 https://doi.org/10.1007/s12020-019-02045-1 REVIEW Thyroid hormone misuse and abuse Victor J. Bernet 1,2 Received: 11 June 2019 / Accepted: 2 August 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Thyroid hormone (TH) plays an essential role in human physiology and maintenance of appropriate levels is important for good health. Unfortunately, there are instances in which TH is misused or abused. Such misuse may be intentional such as when individuals take thyroid hormone for unapproved indications like stimulation of weight loss or improved energy. There are instances where healthcare providers prescribe thyroid hormone for controversial or out of date uses and sometimes in supraphysiologic doses. Othertimes, unintentional exposure may occur through supplements or food that unknowingly contain TH. No matter the reason, exposure to exogenous forms of TH places the public at risk for potential adverse side effects. Keywords Thyrotoxicosis ● Thyroid hormone abuse ● Thyroid hormone misuse ● Factitious thyrotoxicosis ● Supplements ● 1234567890();,: 1234567890();,: Analogs Overdose Thyroid hormone misuse and abuse secondary to exogenous TH ingestion that may be unin- tentional or purposeful such as in some cases of Munch- Almost any substance that impacts body physiology and ausen syndrome. Instances of TH misuse can be associated function is at risk for misuse or frank abuse, usually in the with the development of significant side effects. There are misgiven belief that the particular agent whether it be a other instances of chronic, low-grade over treatment with herb, supplement, medication, or hormone has healing TH, which occur for various misreasoning such as weight properties beyond that of which it actually possesses.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Triiodothyroacetic Acid in Health and Disease
    234 2 S GROENEWEG and others Triac in health and disease 234:2 R99–R121 Review Triiodothyroacetic acid in health and disease Correspondence Stefan Groeneweg, Robin P Peeters, Theo J Visser and W Edward Visser should be addressed Department of Internal Medicine and Academic Center for Thyroid Diseases, Erasmus University to W E Visser Medical Center, Rotterdam, The Netherlands Email [email protected] Abstract Thyroid hormone (TH) is crucial for development and metabolism of many tissues. The Key Words physiological relevance and therapeutic potential of TH analogs have gained attention in f thyroid hormone the field for many years. In particular, the relevance and use of 3,3′,5-triiodothyroacetic f resistance to thyroid hormone (RTH) acid (Triac, TA3) has been explored over the last decades. Although TA3 closely resembles f thyroid hormone analog the bioactive hormone T3, differences in transmembrane transport and receptor isoform- f thyroacetic acid specific transcriptional activation potency exist. For these reasons, the application of TA3 derivatives as a treatment for resistance to TH (RTH) syndromes, especially MCT8 deficiency, is topic of f Triac ongoing research. This review is a summary of all currently available literature about the f TA3 formation, metabolism, action and therapeutic applications of TA3. Endocrinology Journal of Endocrinology of (2017) 234, R99–R121 Journal Introduction Thyroid hormone (TH) is crucial for the development and The deiodinases (D1–3) importantly regulate the bio- metabolism of many tissues. Thyroid stimulating hormone availability of T3 in targets cells, while TH is also (TSH) controls the production and secretion of TH by the metabolized by glucuronidation and sulfation, which thyroid gland, which predominantly produces the pro- enhance biliary excretion (Engler & Burger 1984, Burger hormone thyroxine (T4) and to a lesser extent the bioactive 1986, Visser 1996).
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • In Vitro Inhibition of Breast Cancer Spheroid-Induced Lymphendothelial
    FULL PAPER British Journal of Cancer (2013) 108, 570–578 | doi: 10.1038/bjc.2012.580 Keywords: lymphendothelial intravasation; tumour spheroid; acetohexamide; nifedipin; isoxsuprine; proadifen In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen N Kretschy1,8, M Teichmann1,8, S Kopf1, A G Atanasov2, P Saiko3, C Vonach1, K Viola1, B Giessrigl1, N Huttary1, I Raab1, S Krieger1,WJa¨ ger4, T Szekeres3, S M Nijman5, W Mikulits6, V M Dirsch2, H Dolznig7, M Grusch6 and G Krupitza*,1 1Institute of Clinical Pathology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; 2Department of Pharmacognosy, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria; 3Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; 4Department for Clinical Pharmacy and Diagnostics, Faculty of Life Sciences, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria; 5Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, AKH BT 25.3, A-1090 Vienna, Austria; 6Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria and 7Institute of Medical Genetics, Medical University of Vienna, Waehringer Strasse 10, A-1090 Vienna, Austria Background: As metastasis is the prime cause of death from malignancies, there is vibrant interest to discover options for the management of the different mechanistic steps of tumour spreading. Some approved pharmaceuticals exhibit activities against diseases they have not been developed for. In order to discover such activities that might attenuate lymph node metastasis, we investigated 225 drugs, which are approved by the US Food and Drug Administration.
    [Show full text]
  • List of Ingredients Prohibited in Cosmetic Products This Rule Has Been Translated Into English According to the Original Chinese Version
    List of Ingredients Prohibited in Cosmetic Products This rule has been translated into English according to the original Chinese version. If there is any inconsistency or ambiguity between these two versions, the Chinese version shall prevail. No. Chemical name CAS No. Mercury and its compounds (with the exception of the substance listed in the “List of Preservatives in Cosmetic Products”) 1 7439-97-6 Due to the raw material or other technically unavoidable reasons, the trace amounts of Mercury shall not exceed 1 ppm. 103-16-2/ 2 4-Benzyloxyphenol and 4-ethoxyphenol 622-62-8 3 Bithionol 97-18-7 4 Pilocarpine and its salts 92-13-7 5 Halogeno-salicylanilide - 10043-35-3/ 6 Boric acid 11113-50-1 7 Sodium perborate 7632-04-4 Sodium borate 8 1330-43-4 except for sodium borate used to emulsify beeswax or bleached beeswax, which content should not exceed 0.76% 9 Chlorofluorocarbons - 10 3'-Ethyl-5',6',7',8'-tetrahydro-5',5',8',8'-tetramethyl-2'- acetonaphthone or 7-acetyl-6-ethyl-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphtalen (AETT; Versalide) 88-29-9 11 Cells, tissues or products of human origin - Hydroxy-8-quinoline and its sulphate 148-24-3/ 12 For use as stabilizer of hydrogen peroxide in hair dyes and perming products, the content should not exceed 0.03% (calc. as base) 134-31-6 13 Dichloromethane 75-09-2 14 4-tert-Butyl-3-methoxy-2,6-dinitrotoluene (Musk ambrette) 83-66-9 15 6-Methylcoumarin (Non-medical toothpaste and mouthwash are otherwise specified by law) 92-48-8 16 Vinyl chloride monomer 75-01-4 17 2,2'-Dihydroxy-3,3',5,5',6,6'-hexachlorodiphenylmethane (Hexachlorophene (INN)) 70-30-4 18 Tretinoin (INN) (retinoic acid and its salts) 302-79-4 19 4-Amino-2-nitrophenol 119-34-6 20 Antimony and its compounds 7440-36-0 Arsenic and its compounds 21 7440-38-2 Due to the raw material or other technically unavoidable reasons, the trace amounts of Arsenic shall not exceed 3 ppm.
    [Show full text]
  • Thesis Explores Endocrine Determinants of the Haemostatic Hormone
    UvA-DARE (Digital Academic Repository) Endocrine determinants of haemostasis and thrombosis risk: Focus on thyroid hormone Elbers, L.P.B. Publication date 2016 Document Version Final published version Link to publication Citation for published version (APA): Elbers, L. P. B. (2016). Endocrine determinants of haemostasis and thrombosis risk: Focus on thyroid hormone. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:10 Oct 2021 Endocrine Determinants of Haemostasis and Thrombosis Risk – Risk Thrombosis and of Haemostasis Determinants Endocrine UITNODIGING Voor het bijwonen van de openbare verdediging van het proefschrift This thesis explores endocrine determinants of the haemostatic Endocrine Determinants of system and thrombosis risk with main focus on thyroid hormone. Haemostasis and It describes, in three parts, the effects of thyroid hormone on the Thrombosis Risk haemostatic system, the effects of thyroid hormone (mimetics) Focus on Thyroid Hormone on lipids and the effects of other hormones on the haemostatic system and thrombosis risk.
    [Show full text]
  • ATA/AACE Guidelines
    ATA/AACE Guidelines CLINICAL PRACTICE GUIDELINES FOR HYPOTHYROIDISM IN ADULTS: COSPONSORED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND THE AMERICAN THYROID ASSOCIATION Jeffrey R. Garber, MD, FACP, FACE1,2*; Rhoda H. Cobin, MD, FACP, MACE3; Hossein Gharib, MD, MACP, MACE4; James V. Hennessey, MD, FACP2; Irwin Klein, MD, FACP5; Jeffrey I. Mechanick, MD, FACP, FACE, FACN6; Rachel Pessah-Pollack, MD6,7; Peter A. Singer, MD, FACE8; Kenneth A. Woeber, MD, FRCPE9 for the American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice are systematically developed statements to assist health-care professionals in medical decision making for specific clinical conditions. Most of the content herein is based on literature reviews. In areas of uncertainty, professional judgment was applied. These guidelines are a working document that reflects the state of the field at the time of publication. Because rapid changes in this area are expected, periodic revisions are inevitable. We encourage medical professionals to use this information in conjunction with their best clinical judgment. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances. 988 989 CLINICAL PRACTICE GUIDELINES FOR HYPOTHYROIDISM IN ADULTS: COSPONSORED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND THE AMERICAN THYROID ASSOCIATION Jeffrey R. Garber, MD, FACP, FACE1,2*; Rhoda H. Cobin, MD, FACP, MACE3; Hossein Gharib, MD, MACP, MACE4; James V. Hennessey, MD, FACP2; Irwin Klein, MD, FACP5; Jeffrey I. Mechanick, MD, FACP, FACE, FACN6; Rachel Pessah-Pollack, MD6,7; Peter A.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • Clinical Thyroidology November 2002 Volume 14 Issue 3
    CLINICAL THYROIDOLOGY VOLUME XIV ● ISSUE 3 NOVEMBER 2002 HYPERTHYROIDISM NODULAR GOITER The Dietary Supplement Tiratricol (3,3,5′-Triiodothy- Thyroxine Therapy Does Not Reduce the Size of Benign roacetic Acid) Can Cause Symptoms of Solitary Thyroid Nodules: Systematic Analysis of Hyperthyroidism ..................................................................41 Multiple Studies ....................................................................51 The Serum Free Triiodothyronine to Free Thyroxine THYROID CANCER Ratio and the Peripheral Blood Eosinophil to Monocyte Ratio Help to Distinguish between Graves’ Disease and Completion Thyroidectomy Can Be Done Safely after Thyroiditis as a Cause of Thyrotoxicosis ........................42 Thyroid Lobectomy in Patients with Thyroid Carcinoma..............................................................................52 GRAVES’ DISEASE Changes in Surgical Practice and Use of Postoperative Concordance of Graves’ Disease Is Greater in Monozy- Radioiodine Therapy Have Had Limited Effect on Out- gotic than Dizygotic Twins ................................................43 come in Patients with Papillary Thyroid Carcinoma ......53 Shedding of Part of the Thyrotropin Receptor May Be Fertility Is Not Impaired after Radioiodine Therapy in Important in the Pathogenesis of Hyperthyroidism in Men with Thyroid Carcinoma............................................54 Graves’ Disease ....................................................................44 High Serum Antithyroglobulin Concentrations after Neonatal
    [Show full text]
  • Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
    LEGEMIDDELSTATISTIKK 2019:2 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Christian Lie Berg Kristine Olsen Solveig Sakshaug Utgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2019 Tittel/Title: Legemiddelstatistikk 2019:2 Reseptregisteret 2014–2018 / The Norwegian Prescription Database 2014–2018 Forfattere/Authors: Christian Berg, redaktør/editor Kristine Olsen Solveig Sakshaug Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no / The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon / Contact information: Folkehelseinstituttet / Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8406-014-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2014–2018 [The Norwegian Prescription Database 2014–2018] Legemiddelstatistikk 2019:2, Oslo, Norge: Folkehelseinstituttet, 2019. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian
    [Show full text]